An FDA Panel Just Endorsed These Unproven Peptides

The FDA panel’s endorsement of the “Wolverine stack” underscores how influencer‑driven supplement trends can slip into formal regulatory pathways, even when robust clinical evidence is missing. By adding these amino acids to the FDA’s bulks list, manufacturers will be able to market them as “approved‑type” ingredients, potentially misleading consumers about their safety and efficacy.

Published

23 Jul 2026

Reading Time

2 min read

FDA Panel Recommendation (source)

Direct quotation

“Outside experts — some with a vested interest in peptides — recommended adding a number of the amino acids to the FDA’s bulks list, including the ‘Wolverine stack’ touted by Joe Rogan and other influencers.” – Wired, 23 Jul 2026

Implications

Why it matters

Adding amino acids to the FDA’s bulks list creates a formal pathway for ingredients that have not yet been validated by clinical trials.
The inclusion of a blend popularized by high‑profile influencers raises questions about how marketing influence may intersect with regulatory decisions.

Who is affected

Supplement manufacturers that produce peptide mixes can reference the bulks list to justify production and labeling.
Influencers and media personalities who promote stacks like the “Wolverine stack” may see their recommendations gain a veneer of regulatory endorsement.
Consumers could encounter these products in stores or online platforms with the perception of FDA approval, despite the lack of clinical proof.

What to watch next

Final FDA action: Whether the panel’s recommendation translates into an official update to the bulks list.
Disclosure of expert affiliations: Any further information about the “vested interest” mentioned by the source.
Regulatory response from consumer‑protection agencies or lawmakers concerned with unproven supplement claims.

Source: Wired, “An FDA Panel Just Endorsed These Unproven Peptides,” Thu, 23 Jul 2026 23:45:12 +0000.